-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2418 Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months’ Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Program: Oral and Poster Abstracts
Session: 322. Disorders of Coagulation or Fibrinolysis: Poster II
Hematology Disease Topics & Pathways:
Hemophilia, Diseases, Bleeding and clotting
Sunday, December 8, 2019, 6:00 PM-8:00 PM
Hall B, Level 2 (Orange County Convention Center)

Jerzy Windyga1*, Pal A Holme2*, C. Hermans3, Ana R Cid4*, Nirjhar Chatterjee5*, Hongyu Jiang5*, Viridiana Cano-Garcia6 and Carmen Escuriola7*

1Institute of Hematology and Transfusion Medicine, Warsaw, Poland
2Oslo University Hospital and Institute for Clinical Medicine, University of Oslo, Oslo, Norway
3Division of Hematology, Saint-Luc University Hopital, Brussels, Belgium
4Haemostasis and Thrombosis Unit, University and Polytechnic Hospital La Fe, Valencia, Spain
5Baxalta US Inc., a Takeda company, Cambridge, MA
6Shire International GmbH, a Takeda company, Zug, Switzerland
7HZRM Hamophilie Zentrum Rhein Main GmbH, Frankfurt, Germany

Introduction: The primary objective of the FEIBA Global Outcome study (FEIBA GO) is to describe the long-term, real-world effectiveness and safety of activated prothrombin complex concentrate (aPCC; Feiba®, Baxalta Inc, a Takeda company, Lexington, MA, USA) for preventing and managing bleeding in patients with congenital hemophilia A or B with inhibitors (PwHI) across different clinical settings. This interim >18-month analysis corresponds to the report of May 2019.

Methods: FEIBA GO (EUPAS6691) is an ongoing post-authorization, prospective, observational, multicenter cohort study. Male PwHI diagnosed before study entry and prescribed treatment with aPCC will be followed over 4 years; treatment regimens are prescribed at the physician’s discretion. Ethics approval and patient consent were obtained.

Results: Enrollment was completed on December 31, 2017, with 53 PwHI from 27 sites in 11 countries (hemophilia A: n=52, hemophilia B: n=1; median [range] age at baseline: 18 [2–71] years). Total annualized bleeding rate (ABR) and annualized joint bleeding rate (AJBR) for all bleeds are shown in Table 1 for the 21 patients who received prophylaxis or on-demand aPCC and had >18 months of follow-up data. Of 15 patients who received aPCC prophylaxis, 4 (26.7%) and 7 (46.7%) reported ABRs of ≤3 and AJBRs of ≤3, respectively. All 53 enrolled patients were included in the safety analysis. During the >18 month analysis period, a total of 139 non-serious treatment-emergent adverse events (TEAEs) were reported in 29 of 53 patients (including 9 events in 3 patients probably related to treatment and 2 events in 1 patient possibly related), and 40 serious TEAEs were reported in 17 patients. One possibly related serious TEAE of acute myocardial posterior wall infarction with embolic right coronary artery occlusion was reported in a patient with a catheter port; outcome: recovered/resolved. No thrombotic microangiopathies were reported.

Conclusions: This interim analysis of real-world data at >18 months’ follow-up is consistent with experience and continues to validate the safety and effectiveness of aPCC. Long-term follow-up data over 4 years from FEIBA GO will provide further information on the real-world effectiveness and safety of aPCC as monotherapy.

Disclosures: Windyga: Bayer: Honoraria, Research Funding; CSL Behring: Honoraria, Research Funding; Ferring Pharmaceuticals: Honoraria, Research Funding; Novo Nordisk: Honoraria, Research Funding; Octapharma: Honoraria, Research Funding; Rigel Pharmaceuticals: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Alexion: Honoraria, Research Funding; Alnylam: Honoraria, Research Funding; Baxalta/Shire (a Takeda company): Honoraria, Research Funding; Sanofi: Honoraria, Research Funding; Siemens: Honoraria, Research Funding; Sobi: Honoraria, Research Funding; Werfen: Honoraria, Research Funding. Holme: Sobi: Honoraria, Research Funding; Shire, a Takeda company: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; CSL Behring: Honoraria; Bayer: Honoraria, Research Funding; Octapharma: Research Funding; Novo Nordisk: Honoraria. Hermans: Shire, a Takeda company: Consultancy; Novo Nordisk: Consultancy. Cid: Novo Nordisk: Honoraria; Shire, a Takeda company: Honoraria. Chatterjee: Baxalta US Inc., a Takeda company: Employment, Equity Ownership. Jiang: Baxalta US Inc., a Takeda company: Employment, Equity Ownership. Cano-Garcia: Shire, a Takeda company: Employment, Equity Ownership. Escuriola: Octapharma: Consultancy, Honoraria, Research Funding; Bayer: Consultancy, Honoraria, Research Funding; Sobi: Consultancy, Honoraria, Research Funding; Kedrion: Consultancy, Honoraria, Research Funding; Novo Nordisk: Consultancy, Honoraria, Research Funding; Grifols: Consultancy, Honoraria, Research Funding; Biotest: Consultancy, Honoraria, Research Funding; Shire, a Takeda company: Consultancy, Honoraria, Research Funding; CSL Behring: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding.

*signifies non-member of ASH